Viking Therapeutics's total assets for Q3 2024 were $937.89M, a decrease of -0.95% from the previous quarter. VKTX total liabilities were $26.44M for the fiscal quarter, a 2.25% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.